transfus
transmit
diseas
ttd
caus
virus
protozoa
prion
comprehens
allinclus
list
potenti
ttd
found
tabl
bacteria
transmit
transfus
usual
product
bacteria
donor
product
endotoxin
rather
transfer
infecti
bacteria
caus
posttransfus
bacteriarel
complic
reason
bacteri
contamin
blood
product
method
limit
detect
bacteria
platelet
product
discuss
chapter
book
respect
mitig
transfus
transmiss
infecti
agent
larg
base
donor
select
donor
test
us
around
world
donor
select
test
also
occupi
individu
chapter
text
includ
chapter
chapter
inde
strategi
greatli
effect
lower
residu
risk
ttd
us
shown
figur
final
pathogenreduct
c
h
p
e
r
inactiv
technolog
potenti
elimin
virtual
ttd
though
technolog
approv
use
platelet
plasma
outsid
us
hepat
virus
includ
hepadnavirus
flavivirus
picornavirus
report
transmit
transfus
result
inflamm
liver
primari
clinic
manifest
virus
agent
result
hepat
primari
diseas
symptom
jaundic
dark
urin
hepatomegali
anorexia
malais
fever
nausea
abdomin
pain
vomit
hepat
b
hepat
c
transmit
parenter
ie
contact
blood
bodi
fluid
typic
hepat
virus
transmit
transfus
hepat
hav
tradit
transmit
fecalor
rout
rare
transmit
suffici
amount
viru
present
hepat
hav
picornavirida
famili
usual
result
mild
selflimit
diseas
mortal
rate
less
hepat
result
chronic
infect
viru
typic
transmit
fecalor
rout
result
foodborn
outbreak
prophylaxi
provid
immun
serum
globulin
prevent
vaccin
avail
seroposit
rate
us
approxim
individu
quit
ill
virem
phase
hav
infect
often
feel
well
enough
donat
blood
defer
due
fever
sick
risk
transfus
transmit
hepat
less
case
per
million
transfus
product
solventdeterg
process
use
make
pathogenreduc
plasma
plasma
pool
product
fail
fulli
inactiv
nonenvelop
hav
result
transmiss
occur
result
addit
inactiv
step
test
hav
product
manufactur
larg
pool
plasma
addit
recipi
pool
plasma
product
eg
hemophilia
patient
receiv
hepat
vaccin
hepadnavida
famili
transmit
parenter
sexual
perinat
us
preval
lowpreval
countri
infect
horizont
adult
adult
countri
high
preval
hbv
horizont
vertic
ie
perinat
infect
occur
widespread
vaccin
infant
highrisk
adult
result
decreas
incid
diseas
new
infectionsyear
us
addit
hepat
b
immun
globulin
avail
postexposur
prophylaxi
infant
born
infect
mother
tthbv
may
result
either
acut
infect
subsequ
clearanc
viru
immun
chronic
infect
persist
viral
replic
chronic
infect
may
resolv
develop
immun
may
reactiv
result
acut
diseas
incub
period
usual
day
individu
asymptomat
infect
person
year
age
experi
jaundic
fever
loss
appetit
nausea
vomit
abdomin
pain
infect
individu
usual
year
age
fulmin
acut
infect
result
death
serolog
result
acut
infect
adult
demonstr
hbsag
posit
antihbc
posit
igm
antihbc
posit
antihb
neg
format
antihb
disappear
hbsag
indic
develop
immun
without
clinic
diseas
likelihood
chronic
infect
relat
age
patient
time
infect
person
infect
infanc
yet
person
infect
age
develop
chronic
diseas
chronic
infect
may
asymptomat
individu
develop
sever
fatal
diseas
cirrhosi
hepatocellular
carcinoma
extrahepat
manifest
often
result
cryoglobulinemia
includ
rash
arthriti
vascul
glomerulonephr
serolog
result
patient
chronic
activ
hepat
demonstr
hbsag
posit
antihbc
posit
igm
antihbc
neg
antihb
neg
treatment
chronic
infect
includ
interferon
lamivudin
adefovir
addit
antivir
medic
us
current
use
test
hbsag
antihbc
estim
residu
risk
hbv
transmiss
among
repeat
donor
among
donor
absenc
nucleic
acid
test
nat
estim
depend
assumpt
extrapol
report
posttransfus
infect
transfus
transmit
hbv
may
either
underreport
overreport
mani
case
posttransfus
hbv
infect
may
contract
transfus
one
report
found
case
could
unequivoc
link
transfus
nat
test
hbv
implement
countri
preval
especi
high
us
minipool
approach
nat
sensit
recent
gener
serolog
test
hbsag
hbsag
rise
high
titer
quickli
approxim
time
hbv
dna
ie
minipool
nat
test
significantli
decreas
window
period
infecti
form
hepat
coat
hbsag
therefor
hepat
infecti
presenc
activ
hbv
infect
coinfect
hepat
b
result
seriou
diseas
infect
hepat
b
alon
current
measur
detect
infect
hbv
also
target
elimin
hepat
transfus
transmiss
hepat
c
hepat
c
rna
viru
flavivirida
famili
parenter
transmit
especi
blood
transfus
prior
test
intraven
drug
use
blood
transfus
recipi
evid
hepat
c
infect
use
current
nat
test
risk
estim
million
product
less
incid
new
infect
us
declin
per
year
per
year
http
wwwcdcgov
hepatitishcvhtm
current
seropreval
us
overal
intraven
drug
user
patient
approxim
symptom
fever
jaundic
loss
appetit
fatigu
nausea
acut
infect
incub
period
week
cirrhosi
develop
averag
year
hepatocellular
carcinoma
averag
year
hcv
lead
indic
liver
transplant
us
current
treatment
chronic
infect
includ
interferon
ribavirin
use
current
enzym
immunoassay
test
nat
current
risk
less
frequent
million
donat
posit
test
result
hcv
antibodi
donor
requir
lookback
per
fda
locat
notifi
test
appropri
treat
recipi
product
donat
previous
donor
time
test
posit
hcv
either
yet
acquir
infect
marker
infect
limit
test
detect
http
wwwfdagovcbergdlnshcvlkbkhtm
yield
lookback
low
sinc
implement
nat
test
circa
hepat
e
hepat
e
result
selflimit
hepat
typic
transmit
fecalor
rout
hepat
e
viru
found
predominantli
tropic
countri
rare
case
transfusiontransmit
hepat
e
recent
report
hepat
g
hepat
g
common
normal
popul
normal
individu
antibodi
hepat
g
viral
rna
detect
viru
transfus
transmit
demonstr
high
preval
infect
multipli
transfus
individu
current
diseas
associ
viru
thu
test
requir
ttv
senv
ttv
senv
wide
distribut
transmiss
transfus
current
littl
evid
caus
diseas
recipi
therefor
test
strategi
mitig
transfus
transmiss
virus
warrant
retrovirus
retrovirus
rna
virus
presenc
viral
particleassoci
revers
transcriptas
uniqu
replic
cycl
viru
particl
attach
cell
membran
subsequ
enter
host
cell
revers
transcriptas
enzym
copi
viral
rna
cdna
complementari
doublestrand
dna
cdna
integr
host
cell
genom
subsequ
transcript
process
translat
viral
gene
mediat
host
cell
enzym
particl
bud
cell
membran
infect
cell
addit
viru
spread
fusion
infect
uninfect
cell
replic
integr
viral
dna
mitosi
meiosi
lentiviru
subgroup
retroviru
famili
discov
first
test
licens
donor
screen
hiv
transmiss
intraven
administr
infect
blood
product
highli
effici
hemophiliac
treat
factor
viii
earli
infect
receiv
unit
factor
viii
infect
san
francisco
area
risk
hiv
transfus
product
hiv
infect
transmit
sexual
contact
childbirth
breastfeed
parenter
exposur
blood
cdc
report
us
highest
incid
new
diseas
male
african
american
age
maletomal
sex
new
infect
maletomal
sex
highrisk
heterosexu
contact
intraven
drug
use
http
wwwcdcgovhiv
infect
caus
aid
famili
divid
main
outlier
nonm
nono
n
group
group
distinct
subtyp
clade
ak
us
clade
b
almost
exclus
preval
greatest
genet
divers
central
africa
group
common
cameroon
surround
west
african
countri
repres
hiv
infect
group
infect
us
rare
usual
found
immigr
previou
gener
hiv
antibodi
assay
reliabl
detect
group
current
assay
increas
sensit
group
unusu
variant
still
fda
continu
recommend
perman
deferr
blood
donor
born
resid
travel
west
africa
sinc
sexual
contact
someon
fulfil
criteria
also
rare
us
one
infect
donor
identifi
million
donat
report
case
transfus
transmiss
us
infect
approxim
acut
hiv
infect
result
nonspecif
flulik
ill
incub
period
week
acut
infect
resolv
week
month
result
asymptomat
period
may
last
year
period
hiv
viremia
persist
number
lymphocyt
primari
target
hiv
gradual
declin
loss
lymphocyt
result
opportunist
infect
addit
direct
viral
effect
multipl
organ
togeth
result
death
averag
year
cours
diseas
chang
dramat
advent
potent
antiretrovir
therapi
greatli
prolong
surviv
howev
medic
erad
hiv
multipl
sideeffect
moreov
resist
viral
strain
develop
add
difficulti
treat
hivinfect
patient
donor
includ
serolog
assay
antibodi
minipool
nat
current
estim
hiv
transmiss
less
frequent
million
product
test
expect
unmeasur
frequenc
approxim
million
product
transfus
us
identif
person
receiv
blood
product
donor
later
found
test
posit
hiv
refer
lookback
mandat
fda
cfr
transmit
transfus
predomin
infect
lymphocyt
infect
preferenti
lymphocyt
lesser
extent
infect
lymphocyt
b
lymphocyt
macrophag
seropreval
blood
donor
us
approxim
per
donor
primari
mode
transfus
vertic
transmiss
mother
child
secondari
breast
feed
infect
rate
declin
discontinu
infect
mother
breastfeed
sexual
transmiss
parenter
exposur
intraven
drug
use
infect
htlv
infect
asymptomat
risk
diseas
may
develop
year
infect
associ
lymphoma
adult
tcell
leukemialymphoma
atll
risk
atll
individu
infect
birth
lifetim
lower
risk
infect
adulthood
ie
acquir
htlv
transfus
atll
high
mortal
rate
within
year
diseas
onset
associ
tropic
spastic
paraparesi
also
known
associ
myelopathi
ham
tsp
slowli
progress
myelopathi
character
spastic
paraparesi
lower
extrem
hyperreflexia
bowel
bladder
symptomatolog
risk
tsp
posit
individu
similar
lower
risk
posit
individu
diseas
associ
infect
includ
lymphocyt
pneumon
uveiti
polymyos
arthriti
bronchiti
dermat
infecti
syndrom
rbc
platelet
whole
blood
fresh
frozen
plasma
result
seroconvers
transfus
recipi
product
store
greater
day
transfus
less
like
transmit
viru
us
seroconvers
rate
individu
receiv
seroposit
cellular
compon
report
lookback
studi
recipi
arc
donor
seroconvert
timefram
individu
donat
cellular
compon
none
four
aliv
recipi
agre
test
htlv
seroposit
risk
transfus
transmiss
estim
per
million
product
transfus
herpesvirus
herpesvirus
doublestrand
dna
express
viral
enzym
particip
dna
synthesi
nucleic
acid
metabol
viral
dna
synthesi
packag
confin
host
cell
nucleu
infect
cell
destroy
activ
viral
replic
viru
capabl
latenc
indefinit
cmv
herpesviru
relev
transfus
medicin
leukocytotrop
herpesvirus
ebv
may
also
contamin
blood
product
hpc
solidorgan
transplant
cmv
transmiss
commun
usual
close
contact
person
shed
cmv
seroconvers
rate
blood
donor
approxim
year
rate
year
adolesc
report
preval
rang
rate
increas
age
higher
lower
socioeconom
group
urban
area
develop
countri
approxim
us
blood
donor
cmv
seroposit
infect
immunocompet
individu
mild
selflimit
diseas
cours
fever
malais
hepatosplenomegali
rash
immun
respons
elimin
viru
viru
becom
latent
peripher
blood
leukocyt
transplacent
infect
infect
infant
result
intrauterin
growth
retard
deaf
mental
retard
blind
thrombocytopen
bleed
infect
immunocompromis
patient
includ
prematur
infant
recipi
solidorgan
hpc
transplant
aid
patient
lead
pneumon
hepat
retin
multisystem
organ
failur
may
result
death
treatment
cmv
infect
includ
antivir
ganciclovir
cidofovir
foscarnet
cmv
infect
detect
anticmv
antibodi
cmv
antigenemia
assay
use
immunostain
identifi
quantit
peripher
blood
leukocyt
contain
cmv
protein
cmv
pcr
pcr
allow
earlier
detect
cmv
larg
replac
need
cmv
antigenemia
assay
leukocyt
primari
mode
transfus
transmiss
cmv
therefor
leukoreduct
greatli
decreas
risk
cmv
transmiss
transfus
lead
activ
cmv
infect
recipi
transfus
transmit
cmv
seroneg
recipi
transfus
cmvinfect
product
reactiv
cmv
infect
cmvseroposit
recipi
experi
reactiv
latent
infect
transfus
cmvneg
product
cmv
superinfect
seroposit
recipi
contract
new
strain
cmv
cmvposit
product
transfus
transmit
cmv
import
caus
morbid
mortal
immunocompromis
patient
immunocompromis
patient
includ
low
birthweight
neonat
contract
cmv
transfus
unscreen
unleukoreduc
blood
product
recipi
receiv
seroneg
blood
product
acquir
cmv
recipi
receiv
leukoreduc
blood
product
acquir
cmv
base
number
differ
report
studi
indic
cmvsafe
product
defin
leukoreduc
andor
anticmv
neg
review
chapter
epstein
barr
viru
epstein
barr
viru
ebv
associ
varieti
diseas
includ
infecti
mononucleosi
burkitt
lymphoma
nasopharyng
carcinoma
ebv
infect
usual
infect
saliva
acut
infect
children
asymptomat
character
sore
throat
enlarg
lymph
node
acut
infect
adult
result
infecti
mononucleosi
fever
tonsillar
infect
enlarg
lymph
node
hematolog
immunolog
abnorm
hepat
organ
involv
ebv
infect
b
lymphocyt
remain
latent
occasion
case
posttransfus
ebv
infect
report
screen
ebv
perform
high
preval
seroposit
donor
activ
infect
infecti
mononucleosi
usual
symptomat
leukoreduct
may
prevent
decreas
risk
transfus
transmiss
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
primarili
transmit
sexual
contact
incid
us
blood
donor
one
studi
us
demonstr
risk
seroconvers
per
transfus
compon
studi
uganda
seropreval
rate
approxim
show
seroconvers
rate
transfus
seroposit
product
propos
method
reduc
risk
transfus
transmiss
includ
leukoreduct
donor
test
pathogen
reduct
parvoviru
infect
parvoviru
usual
result
asymptomat
mild
symptom
rash
vomit
ach
joint
limb
fatigu
malais
erythema
infectiosum
fifth
diseas
infect
sickl
cell
diseas
thalassemia
patient
may
result
aplast
crisi
immunocompromis
individu
especi
hivposit
individu
parvoviru
infect
may
result
aplast
anemia
infect
pregnanc
may
result
sever
fetal
anemia
malform
infant
seroposit
rate
blood
donor
transmit
either
releas
viru
upper
respiratori
tract
parenter
viremia
appear
within
first
week
persist
week
chronic
infect
occur
rare
case
transfus
transmiss
blood
product
report
parvoviru
destroy
solventdeterg
treatment
heat
inactiv
seroconvers
recipi
solventdeterg
treat
plasma
addit
viral
inactiv
step
well
nat
test
implement
plasma
would
pool
use
manufactur
plasma
deriv
infect
infect
often
asymptomat
result
chronic
infect
viremia
persist
less
day
incub
period
approxim
day
follow
rang
symptom
includ
mild
fever
headach
rash
eye
pain
vomit
lymphocytopenia
muscl
weak
flaccid
paralysi
poliomyel
peripher
demyelin
approxim
infect
result
sever
neurolog
diseas
especi
age
year
prevent
avoid
mosquito
mosquito
bite
plasmodium
spp
malaria
four
known
plasmodium
speci
result
malaria
human
p
falciparum
p
malaria
p
vivax
p
oval
incub
period
rang
day
depend
speci
p
falciparum
result
seriou
infect
fatal
compar
speci
transmiss
human
mosquito
lifecycl
split
mosquito
human
merozoit
form
infect
rbc
replic
result
rbc
burst
releas
organ
blood
infect
rbc
infect
usual
last
year
last
year
case
p
malaria
infect
malari
infect
result
fever
chill
headach
hemolyt
anemia
splenomegali
diagnosi
examin
thickand
thinblood
smear
varieti
medic
use
prophylaxi
treatment
malaria
risk
malaria
case
per
million
transfus
symptom
infect
includ
fever
chill
headach
hemolysi
occur
week
sever
month
transfus
transfus
transmit
infect
rare
fatal
usual
result
transmiss
p
falciparum
prevent
malari
transmiss
donor
deferr
requir
person
malaria
preced
year
defer
travel
endem
area
defer
year
immigr
endem
area
defer
year
leav
area
malari
risk
area
avail
cdc
websit
http
wwwcdc
govmalariariskmap
mexico
south
central
america
increas
preval
southern
us
immigr
endem
area
transmit
human
bite
reduvid
bug
lifecycl
split
two
host
acut
infect
asymptomat
mild
rare
site
entri
evolv
erythemat
nodul
call
chagoma
may
accompani
fever
hepatosplenomegali
younger
children
may
develop
acut
myocard
meningioenceph
acut
infect
resolv
without
treatment
lifelong
lowlevel
parasitemia
persist
chronic
infect
individu
develop
cardiac
gastrointestin
symptom
year
decad
later
transmiss
transfus
second
major
sourc
human
infect
especi
endem
area
seven
case
transfus
transmiss
us
canada
report
fda
licens
screen
test
antibodi
cruzi
blood
donor
test
us
blood
suppli
demonstr
donor
confirm
posit
major
infect
donor
florida
california
toxoplasma
gondii
toxoplasmosi
infect
gondii
occur
adult
countri
cat
mice
intermedi
host
acut
infect
healthi
individu
usual
asymptomat
infect
immunocompromis
individu
result
sever
diseas
cn
involv
myocard
pneumonia
congenit
infect
give
rise
seriou
complic
includ
liver
cn
diseas
abort
stillbirth
acut
infect
resolv
antibodi
format
organ
remain
latent
leukocyt
transmiss
transfus
document
immunocompromis
individu
prevent
transfus
transmiss
appear
possibl
leukoreduct
evalu
b
divergen
europ
transmit
tick
bite
symptom
babesiosi
rang
mild
sever
ill
hemolysi
fever
infect
last
year
occur
rbc
site
replic
case
transfus
transmiss
babesiosi
occur
us
estim
risk
part
connecticut
furthermor
pcr
studi
reveal
donor
connecticut
parasitem
transfus
transmit
diseas
occur
fever
develop
week
transfus
may
associ
chill
headach
hemolysi
hemoglobinuria
rare
lifethreaten
hemolyt
anemia
renal
failur
coagulopathi
asplen
elderli
sever
immunocompromis
patient
risk
sever
infect
donor
select
current
use
prevent
transfus
transmiss
includ
collect
blood
area
diseas
vector
endem
spring
summer
month
futur
strategi
prevent
diseas
transmiss
especi
highrisk
area
potenti
includ
serolog
nat
test
three
form
leishmaniasi
cutan
mucocutan
viscer
kalaazar
organ
transmit
bite
sandfli
leishmania
speci
restrict
particular
phlebotomu
speci
reservoir
organ
includ
rodent
small
wild
mammal
lifecycl
split
sandfli
mammal
human
organ
invad
reticuloendotheli
system
replic
releas
back
blood
parasitemia
gener
transient
low
level
therefor
risk
transfus
transmiss
low
outsid
us
transfus
transmiss
l
donovani
caus
viscer
leishmaniasi
report
veteran
serv
persian
gulf
defer
donat
year
upon
leav
prion
prion
diseas
result
benign
form
prion
protein
prp
chang
insolubl
proteaseresist
form
prp
sc
lead
format
plaqu
brain
bovin
spongiform
encephalopathi
bse
initi
describ
cattl
uk
bse
transmit
food
chain
meat
bone
meal
ban
rumin
protein
cattl
feed
result
decreas
incid
bse
bse
transmit
human
food
chain
result
variant
creutzfeldtjakob
diseas
vcjd
uk
vcjd
differ
classic
cjd
earlier
age
onset
slower
diseas
progress
higher
level
prp
sc
brain
diseas
present
behavior
chang
dysasthesia
progress
cerebellar
ataxia
dementia
death
month
major
case
vcjd
appear
uk
also
report
european
countri
least
four
case
transfus
transmiss
vcjd
occur
uk
estim
transfus
transmiss
donor
develop
vcjd
within
sever
year
donat
recipi
surviv
longer
year
posttransfus
prevent
includ
deferr
donor
resid
uk
europ
month
use
filter
remov
prion
remov
approxim
half
infect
emerg
infect
numer
potenti
emerg
infect
dengu
fever
sar
influenza
lcmv
requir
continu
surveil
blood
suppli
evalu
intervent
